SCHEMBL2472231

SCHEMBL2472231

COC(=O)C1CCC(Oc2cccc(Cl)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
EPHX2 P34913 1/20 0.47
CCR3 P51677 1/20 0.43
ABL1 P00519 1/20 0.43
HSD17B10 Q99714 1/20 0.42
FPR2 P25090 1/20 0.42
PROKR1 Q8TCW9 1/20 0.42
GRM5 P41594 1/20 0.42
OGG1 O15527 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TNKS O95271 2/20 0.41
PARP1 P09874 1/20 0.41
PARP2 Q9UGN5 1/20 0.41
SCN9A Q15858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2472228 1.00 SLC6A4 (0.49) SLC6A4SLC6A2SLC6A3EPHX2CCR3
SCHEMBL20064278 0.87 SLC6A4 (0.54) SLC6A4SLC6A2SLC6A3EPHX2CCR3
SCHEMBL21222580 0.87 SLC6A4 (0.54) SLC6A4SLC6A2SLC6A3EPHX2CCR3
SCHEMBL2472743 0.86 SLC6A2 (0.51) SLC6A4SLC6A2SLC6A3EPHX2CCR3
SCHEMBL2472739 0.86 SLC6A2 (0.51) SLC6A4SLC6A2SLC6A3EPHX2CCR3
SCHEMBL2469560 0.84 ACSL1 (0.54) SLC6A4SLC6A2SLC6A3EPHX2SMN1; SMN2
SCHEMBL2469558 0.84 ACSL1 (0.54) SLC6A4SLC6A2SLC6A3EPHX2SMN1; SMN2
SCHEMBL30663064 0.83 SLC6A4 (0.49) SLC6A4SLC6A2SLC6A3EPHX2SMN1; SMN2
SCHEMBL2474377 0.82 SLC6A4 (0.48) SLC6A4SLC6A2SLC6A3EPHX2ABL1
SCHEMBL2474378 0.82 SLC6A4 (0.48) SLC6A4SLC6A2SLC6A3EPHX2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2370441-B1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-09-11 EP disclosed
US-8461152-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2013-06-11 US disclosed
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES SCHNIDER PATRICK (CH) 2012-09-06 US disclosed
US-8227458-B2 Arylcyclohexylethers of dihydrotetraazabenzoazulenes HOFFMANN-LA ROCHE INC. (US) 2012-07-24 US disclosed
EP-2370441-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-10-05 EP disclosed
WO-2010060836-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-06-03 WO disclosed
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES HOFFMANN-LA ROCHE, INC. 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225865-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 SLC6A4 887/4885SLC6A2 1065/4885SLC6A3 321/4885
US-20100137286-A1 ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES AVPR1A, AVPR1B, AVPR2 SLC6A4 887/4885SLC6A2 1065/4885SLC6A3 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.